Mehr zum Buch
Multiple Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians. Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease. This book is for all neurologists, primary care physicians, and patients concerned about the treatment of MS. It will also be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, to the pharmaceutical industry and to MS societies.
Buchkauf
Multiple Sclerosis, Donald E. Goodkin, Richard A. Rudick
- Sprache
- Erscheinungsdatum
- 1997
- product-detail.submit-box.info.binding
- (Hardcover),
- Buchzustand
- Gebraucht - Sehr gut
- Preis
- 1,99 €inkl. MwSt.
Keiner hat bisher bewertet.
- Titel
- Multiple Sclerosis
- Untertitel
- Advances in Clinical Trial Design, Treatment and Future Perspectives
- Sprache
- Englisch
- Autor*innen
- Donald E. Goodkin, Richard A. Rudick
- Verlag
- Springer
- Erscheinungsdatum
- 1997
- Einband
- Hardcover
- Seitenzahl
- 364
- ISBN10
- 3540760180
- ISBN13
- 9783540760184
- Reihe
- Schlagwörter
- Medizin, Gesammelte Werke, Forschung, Neurologie, Innere Medizin, Allgemeinmedizin, Lebensqualität, Medizinische Forschung, Multiple Sklerose
- Beschreibung
- Multiple Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians. Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease. This book is for all neurologists, primary care physicians, and patients concerned about the treatment of MS. It will also be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, to the pharmaceutical industry and to MS societies.